Testing AP1189 for newly diagnosed active rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests an oral drug called AP1189 for people just diagnosed with active rheumatoid arthritis who haven't yet taken standard arthritis medicines. You may be able to take part if your disease is very active and you're ready to try a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with rheumatoid arthritis (within the last 6 months).
- You must not have taken any disease-modifying drugs (DMARDs) for RA before.
- You need to have at least 6 painful joints and 6 swollen joints at your screening visit.
- Your RA should be considered 'highly active' based on a special score (DAS28 > 5.1 and CDAI > 22).
- You must have a positive blood test for rheumatoid factor or anti-CCP antibodies, or have a higher level of inflammation if those are negative.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called A-319 for people with active rheumatoid arthritis (RA) that hasn't improved enough after trying other treatments. The goal is to see if A-319 can reduce joint pain, swelling, and inflammation.
This study follows different groups of people—from those at high risk of developing rheumatoid arthritis to those recently diagnosed—to learn more about the disease. By joining, you help researchers understand who gets RA and why, which may lead to earlier detection and better care.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.